Brain Stimulation for Gastrointestinal Disorders
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores how non-invasive brain stimulation might assist with gut issues such as IBS (Irritable Bowel Syndrome) and functional dyspepsia (chronic stomach discomfort). The primary goal is to determine if this brain-focused treatment can enhance the body's self-regulation and potentially lead to new therapies for gut problems. The trial uses repetitive transcranial magnetic stimulation (rTMS) before meals to assess its effects on gut function. Individuals who frequently experience symptoms like bloating or discomfort from IBS or dyspepsia, as well as those without any gut symptoms, might be suitable candidates for this trial. As an unphased trial, it offers a unique opportunity to contribute to groundbreaking research that could lead to innovative treatments for gut issues.
Will I have to stop taking my current medications?
The trial requires that you stop taking certain medications that can lower the seizure threshold, such as some antidepressants and recreational drugs. If you are on any of these, you would need to stop them to participate.
What prior data suggests that this brain stimulation technique is safe for gastrointestinal disorders?
Research has shown that repetitive transcranial magnetic stimulation (rTMS) is generally safe. This non-invasive technique does not require surgery or entering the body and has been used safely to treat conditions like irritable bowel syndrome (IBS). In these studies, the most common side effects were mild, such as headaches or scalp discomfort, while serious side effects were rare.
For instance, one study found that rTMS could affect the interaction between the brain and gut without major safety concerns. Another study used rTMS to help reduce stomach pain in IBS patients and reported no significant safety issues. These findings suggest that rTMS is a safe option for studying its effects on digestive health.12345Why are researchers excited about this trial?
Most treatments for gastrointestinal disorders like IBS and functional dyspepsia involve medications that target symptoms, such as antispasmodics, laxatives, or dietary changes. But rTMS (repetitive transcranial magnetic stimulation) works differently, focusing on the brain-gut connection. Researchers are excited about rTMS because it uses magnetic fields to stimulate nerve cells in the brain, which might help regulate gut activity and alleviate digestive symptoms. This non-invasive approach could offer a new way to manage these conditions without the side effects common in traditional medications.
What evidence suggests that rTMS might be an effective treatment for gastrointestinal disorders?
Research suggests that repetitive transcranial magnetic stimulation (rTMS), the treatment under study in this trial, might improve symptoms in individuals with digestive issues like irritable bowel syndrome (IBS). Studies have found that rTMS can alter brain-gut communication, potentially relieving IBS symptoms. Some research indicates that rTMS can enhance control over bowel movements and emotions, which are often affected in IBS. Additionally, researchers are studying rTMS for its potential to regulate the autonomic nervous system, which manages digestion and other automatic body functions. While more research is needed, early results show promise for rTMS as a treatment for digestive disorders.12456
Who Is on the Research Team?
David J Levinthal, MD/PhD
Principal Investigator
University of Pittsburgh
Are You a Good Fit for This Trial?
This trial is for adults aged 21-60 with gastrointestinal issues like functional dyspepsia or irritable bowel syndrome, as well as healthy individuals without these symptoms. It's not for pregnant people, those with a BMI over 35, metal implants, history of gastric surgery, heavy alcohol use, certain medication users, or those with heart problems.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Baseline Session
Measures of autonomic activity (EGG, ECG, CI) are monitored before and after consumption of a test meal, water, or a nutrient drink. MEPs are assessed before and after the meal or drink.
Treatment
Repetitive transcranial magnetic stimulation (rTMS) is applied before the meal or drink. Responses to symptom surveys are used to characterize subjects.
Follow-up
Participants are monitored for changes in physiological reactivity and correlated with assessments of disease severity, mood, and quality of life.
What Are the Treatments Tested in This Trial?
Interventions
- rTMS
rTMS is already approved in United States, European Union for the following indications:
- Obsessive-Compulsive Disorder (OCD)
- Major Depressive Disorder
- Migraines
- Smoking cessation
- Obsessive-Compulsive Disorder (OCD)
- Major Depressive Disorder
Find a Clinic Near You
Who Is Running the Clinical Trial?
David Levinthal
Lead Sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Collaborator